Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

hadn't heard of this company, thx for flagging... at some point, it would be nice to be updated on any MTA deals CTIX struck with academic centers and the med device division of a (yet unnamed) large Pharma -- all twd researching addtl Brilacidin applications. the PolyCide potential, industrial-material uses, is huge. why i'd love to see Richard Scott, formerly of Polymedix (now at Fox Chase), added as a clinical advisor-----perfectly suited to advance things. just like, if wishes were fishes, getting DeGrado and Klein and Tew, also would be a coup..... the original researchers behind Brilacidin and other HDP-Mimetic compounds.

MTA agreements

EXCERPT
http://cellceutix.com/cellceutix-signs-material-transfer-agreements-for-defensin-mimetic-compounds-with-leading-universities/

Separately, Cellceutix recently presented its defensin mimetics and antimicrobials at the facilities of one of the world’s largest pharmaceutical companies. Discussions are progressing towards a material transfer agreement as the pharma wishes to research the compounds for a variety of uses, although Cellceutix makes no assurances of a final agreement being reached.
[...]
“The material transfer agreements are an important step in the development of our pipeline in addition to our ongoing clinical trials and laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “We were very confident in the value of defensin mimetics when we acquired these assets last September and are extremely pleased that other leading organizations are recognizing the litany of potential uses for these unique compounds. The presentation at the request of the global pharmaceutical company went very well and we are hopeful to move forward with a material transfer agreement, with the understanding that these things take time when dealing with a large pharmaceutical firm.”

EXCERPT
http://cellceutix.com/cellceutix-december-to-be-momentous-month-in-companys-history/#sthash.p9M9vssg.dpuf

Looking to Brilacidin, the lead drug candidate in the Company’s definsin-mimetic platform, Cellceutix has signed an agreement with a division of one of the largest U.S. pharmaceutical companies for testing Brilacidin as a component of certain implanted devices as a means to prevent infection. This potential prophylactic use was not part of Cellceutix’s strategic plans for Brilacidin, but given the compilation of clinical and laboratory data, it is a logical application that could potentially add millions of dollars of revenue to the Company. The material transfer does not cover the pharmaceutical use of Brilacidin for treatment of infections or other diseases. A final contract can only be entered into if and when Brilacidin receives Food and Drug Administration (FDA) approval.

OLDER ARTICLE
Synthetic Polymer Mimics Antimicrobial Properties of Host-Defense Proteins (Sept 2010)
http://www.qmed.com/mpmn/article/synthetic-polymer-mimics-antimicrobial-properties-host-defense-protein

EXCERPT

“Many types of medical devices—such as surgical sutures, catheters, intravenous tubing, implantable joints, bandages, and wound dressings—could benefit from our antimicrobial material,” Landekic says. Like host-defense proteins, which have developed resistance to bacteria over hundreds of millions of years, the PolyCides offer broad resistance against bacteria, as evidenced by 18 sets of serial passage experiments and single-point mutation assays. Landekic concludes, “PolyMedix has thus learned from nature to mimic one of the oldest and most effective immune system defenses against bacterial infection.”